Large-Scale Pharmacogenomics Analysis of Patients With Cancer Within the 100,000 Genomes Project Combining Whole-Genome Sequencing and Medical Records to Inform Clinical Practice SOC was dominated by ...

Modeling at 2023 net pricing estimated semaglutide would avert >358,000 cardiovascular events/deaths, saving ~$15B in cardiovascular care plus ~$8B in other care, but adding ~$344B lifetime drug spend ...

Analysis of data from a randomized trial finds trabeculectomy typically is the better financial bet than tube shunt surgery as a first option to treat glaucoma.

There’s nothing worse than wrapping yourself in a blanket, turning the heater on, and still feeling a cold breeze sneaking in through your window. But the good news is that you don’t always need ...

Discover seven cost-effective marketing methods to grow your small business's customer base through digital, traditional, and ...

Please provide your email address to receive an email when new articles are posted on . For patients with obesity, bariatric surgery was more cost-effective than GLP-1 receptor agonists. The biggest ...

Research led by a Northwestern Medicine team found that, despite higher upfront costs, bariatric surgeries offer two more quality years of life compared to GLP-1 therapies. The long-term ...

Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial We derived disease progression and therapy ...

Discover how growing your own garden can save money, enhance grocery budgets, and yield fresh, organic produce with minimal investment. Cost-effective gardening tips included.

Lifetime treatment with statins is a cost-effective therapy across a wide range of elderly patients with and without cardiovascular disease, according to an analysis published this week in Heart.

For initial treatment of eosinophilic esophagitis (EoE), an elimination diet is the most cost-effective option from a payer perspective and proton pump inhibitor (PPI) therapy is more cost-effective ...

Tirzepatide demonstrated superior cost-effectiveness compared to semaglutide for knee OA and obesity, with a $57,400 per QALY threshold. The Osteoarthritis Policy Model assessed cost-effectiveness, ...